Polyrizon Reports NASARIX Biocompatibility Results, Supporting Advancement To First-In-Human Clinical Trial
Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial Raanana, Israel, July 02, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development